Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option

BJU Int. 2005 Nov;96(7):970-6. doi: 10.1111/j.1464-410X.2005.05739.x.
No abstract available

Publication types

  • Review

MeSH terms

  • Administration, Intravesical
  • Antimetabolites, Antineoplastic / administration & dosage*
  • Antimetabolites, Antineoplastic / adverse effects
  • Antimetabolites, Antineoplastic / therapeutic use
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / therapeutic use
  • Drug Administration Schedule
  • Gemcitabine
  • Humans
  • Patient Selection
  • Urinary Bladder Neoplasms / drug therapy*

Substances

  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Gemcitabine